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Diverse lines of evidence suggest that amyloid- (A) pep-
tides causally contribute to the pathogenesis of Alzheimer dis-
ease (AD), themost frequent neurodegenerative disorder. How-
ever, the mechanisms by which A impairs neuronal functions
remain to be fully elucidated. Previous studies showed that sol-
uble A oligomers interfere with synaptic functions by deplet-
ing NMDA-type glutamate receptors (NMDARs) from the neu-
ronal surface and that overexpression of the receptor tyrosine
kinase EphB2 can counteract this process. Through pharmaco-
logical treatments and biochemical analyses of primary neuro-
nal cultures expressing wild-type or mutant forms of EphB2, we
demonstrate that this protective effect of EphB2 depends on its
PDZ-binding motif and the presence of neuronal activity but
not on its kinase activity. We further present evidence that the
protective effect of EphB2 may be mediated by the AMPA-type
glutamate receptor subunit GluA2, which can become associ-
ated with the PDZ-binding motif of EphB2 through PDZ
domain-containing proteins and can promote the retention of
NMDARs in the membrane. In addition, we show that the
A-induced depletion of surface NMDARs does not depend on
several factors that have been implicated in the pathogenesis
ofA-inducedneuronal dysfunction, including aberrant neuro-
nal activity, tau, prion protein (PrPC), and EphB2 itself. Thus,
although EphB2 does not appear to be directly involved in the
A-induced depletion of NMDARs, increasing its expression
may counteract this pathogenic process through a neuronal
activity- and PDZ-dependent regulation of AMPA-type gluta-
mate receptors.
Alzheimer disease (AD)3 is the most common neurodegen-
erative disorder, affecting millions of elderly people worldwide
(1). Disease-modifying treatments are urgently needed because
the number of AD patients is rising as many populations across
the world live longer, reaching ages at which the risk of AD is
high. It is likely that the development of such treatments will
require a deeper understanding of AD pathogenesis, which
appears to be multifactorial (2). Diverse lines of evidence sug-
gest that amyloid- (A) oligomers causally contribute to cog-
nitive impairments associated with AD at least partly by alter-
ing synaptic activity (2–6). Synaptic activity and cognition
critically depend on the function of NMDA-type glutamate
receptors (NMDARs) and AMPA-type glutamate receptors
(AMPARs), both of which appear to be affected by A oligo-
mers. Indeed, A oligomers deplete and dysregulate NMDARs
(7–12) and AMPARs (9, 13, 14). However, the precise molecu-
lar paths that lead from A oligomers to alterations in these
glutamate receptors remain to be elucidated.
Several factors, including tau, aberrant network activity, and
prion protein (PrPC), may mediate or enable A-induced neu-
ronal dysfunctions. We and others showed that tau reduction
prevents synaptic, network, and behavioral abnormalities in
multiple human amyloid precursor protein (hAPP) transgenic
mouse lines that have pathologically elevated levels of A olig-
omers in brain (15–18). Several studies suggest that aberrant
excitatory network activity, which tau reduction can block (15–
17), contributes to synaptic and cognitive deficits in hAPPmice
and in patients with early stages of AD (19–23). PrPC has also
been reported to be required forA-induced neuronal and cog-
nitive impairments and has been proposed to mediate A-in-
duceddepletion ofNMDARs (24–27), although several of these
findings could not be reproduced by other groups (28–30).
Another interesting molecule that may connect A oligo-
mers to glutamate receptors is the receptor tyrosine kinase
EphB2 (12, 31, 32), which regulates the trafficking and function
ofNMDARs (33). A oligomers directly bind to EphB2 (32) and
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cause its degradation (32). Neuronal overexpression of
hAPP/A in transgenicmice or neuronal knockdown of EphB2
in wild-type mice each impaired long term potentiation and
NMDAR-mediated currents (32). Furthermore, normalizing
EphB2 levels in the dentate gyrus of hAPP mice reversed some
of their synaptic and cognitive impairments (32). Taken
together, these findings motivated us to investigate the rela-
tionship amongA oligomers, EphB2, and glutamate receptors
in greater detail and to determine the extent to which their
interactions depend on tau, PrPC, and neuronal activity.
Experimental Procedures
Mice—Mapt knock-out (tau-deficient) mice (34) were kindly
provided by Dr. Hana Dawson (Duke University) and were
maintained on a C57Bl/6J background. Prnp knock-out (PrPC-
deficient) mice (B6.129S7-Prnptm1Cwe/Orl) (35) were acquired
from the European Mutant Mouse Archive and had been
crossed onto the C57Bl/6J strain for 10 generations. Ephb2
knock-out (EphB2-deficient)mice (36) were kindly provided by
Dr. Mark Henkemeyer (University of Texas Southwestern).
They were obtained on a CD1 background and rederived using
C57Bl/6J females.
RecombinantAOligomers—Unless indicated otherwise, the
A oligomers we used to treat primary neuronal cultures were
prepared from recombinant A peptides, and statementsmade
about A oligomers refer to this type of A assembly. In brief,
hydroxyfluroisopropanol-treated recombinant A peptides
(-amyloid(1–42), ultra pure, hydroxyfluroisopropanol from
rPeptide, catalogue numberA1163, 0.5mg, primary lot number
9131142H) were first dissolved in 22 l of DMSO (at2.5 mM
A(1–42) peptides, monomer equivalent) and then further
diluted with 978l of ice-cold Neurobasal Amedium to gener-
ate a 50 M A(1–42) solution. The A(1–42) solution was
incubated at 4 °C for 24 h to oligomerize A(1–42) peptides.
Vehicle solution was prepared by following the same protocol
except for omitting addition of A(1–42) peptides. On the day
of the experiment, the concentration of A(1–42) peptides was
determined by bicinchoninic acid (BCA) assay (Thermo Scien-
tific, 23225), and vehicle control or oligomerized A(1–42)
peptides (final concentration of 2 M monomer equivalent)
were applied to primary neuronal cultures.
To characterize A oligomers by atomic force microscopy
(AFM), A(1–42) peptides dissolved in 22 l of DMSO were
diluted with 978 l of ice-cold Dulbecco’s phosphate-buffered
saline without calcium or magnesium (DPBS-no Ca2/Mg2;
Life Technologies, 14190-144) because Neurobasal medium
contains factors that interfere with AFM analysis. When added
to the medium of neuronal cultures, A oligomers prepared in
DPBS-no Ca2/Mg2 depleted cell surface GluN1 and EphB2
after 2 and 48 h, respectively (data not shown), confirming their
bioactivity.
Size Exclusion Chromatography (SEC) and A ELISA—We
collected culture medium containing A oligomers 2 and 48 h
after treating cultured neurons and injected it onto a Superdex
75 (10/300GL) column (GE Healthcare) calibrated using a gel
filtration standard kit (Bio-Rad, 151-1901). Samples were
eluted with 1 column volume of phosphate-buffered saline
(PBS) at a flow rate of 0.8 ml/min into 1-ml SEC fractions.
Eluted fractions were further diluted 1:1000, 1:2000, and 1:4000
for A(1–42) ELISA, which was performed as described (37).
Primary Hippocampal Mouse Neurons—Unless indicated
otherwise, experimentswere carried out on primary hippocam-
pal mouse neurons. Hippocampi of newborn mouse pups (P0-
P1) were dissected in ice-cold Earle’s balanced salt solution
without CaCl2, MgSO4, and phenol red (Life Technologies,
14155). Dissected hippocampi were digested with papain
(Worthington, LK003176;1 unit per hippocampus) in Earle’s
balanced salt solution at 37 °C for 15min and then triturated in
a disposable plastic tube in low ovomucoid solution containing
1.5 mg/ml BSA (Sigma-Aldrich, A7030-10G), 1.5 mg/ml tryp-
sin inhibitor (Sigma-Aldrich, T9253-5G), and 66.7 units/ml
DNase I (Sigma-Aldrich, D5025) in DPBS (Life Technologies,
14040-182). After removing debris with a 70-mnylon strainer
(BD Biosciences, 352350), neurons were spun at 1000 rpm for 5
min. Cell pellets were gently dissociated in Neurobasal A
medium supplemented with 1 B27 (Life Technologies,
17504-044), 2.4 mM L-glutamine (Life Technologies, 25030-
081), and 100 units/ml penicillin/streptomycin (Life Technol-
ogies, 15410-122). They were then plated on poly-D-lysine-
coated 12-well plates at a density of 500,000 neurons/well for
Western blot analyses and 1,000,000 neurons/coverslip for
proximity ligation assay. Half of the medium was replaced with
new medium every week, and neurons were used for experi-
ments at DIV 10–14.
Biotinylation and Isolation of Cell Surface Proteins—Cell sur-
face proteins were biotinylated and isolated using a cell surface
protein isolation kit (Thermo Scientific, 89881). After various
treatments, primary hippocampalmouse neurons (DIV 10–14)
were washed once with ice-cold PBS and then incubated with
sulfo-NHS-SS-biotin (sulfosuccinimidyl-2-(biotinamido)-ethyl-
1,3-dithiopropionate; 0.25mg/ml in ice-cold PBS) for 30min at
4 °C. After quenching the biotinylation reaction, neurons were
washed twicewith ice-coldTris-buffered saline (TBS) and lysed
in Pierce IP Lysis Buffer (Thermo Scientific, 87788) with Halt
protease and phosphatase inhibitor mixture (Thermo Scien-
tific, 78440). Lysates were then sonicated on ice using five 1-s
bursts and centrifuged at 1000 rpm for 5min at 4 °C followed by
determination of protein concentration by BCA protein assay.
To isolate biotinylated surface proteins, 30 g of biotinylated
total protein was incubated with NeutrAvidin gel slurry (25 l)
at room temperature for 1 h followed by two washes with TBS
and two additional washes with Pierce IP Lysis Buffer. Isolated
biotinylated proteins were then solubilized in loading buffer for
Western blot analyses.
Western Blot Analysis—Equal amounts of total protein (15
g per lane), or entire eluate from 25 l of NeutrAvidin gel
incubated with 30 g of biotinylated protein lysate, in 1
NuPAGE lithium dodecyl sulfate sample buffer (Life Technol-
ogies, NP0007) and 1 Sample Reducing Agent (Life Technol-
ogies, NP0009) were loaded per gel lane. Protein samples were
electrophoresed on NuPAGENovex 4–12% Bis-Tris Midi pro-
tein gels (Life Technologies,WT1403A) in 1NuPAGEMOPS
SDS running buffer (Life Technologies, NP0001-02) at 200 V
for 1 h at room temperature. Gels were transferred to nitrocel-
lulose membranes using an iBlot gel transfer device (Life Tech-
nologies). Membranes were blocked with Odyssey blocking
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buffer (LI-COR Biosciences, 927-40000) for 1 h at room tem-
perature and then incubated with the primary antibodies listed
in Table 1 overnight at 4 °C.MembraneswerewashedwithTBS
containing 0.05% Tween 20 (TBST) four times for 5 min at
room temperature and then incubated with matching second-
ary antibodies conjugated to IRDye (Li-COR Biosciences; 0.1
g/ml) for 1 h at room temperature followed by washes in
TBST (4  5 min). Protein bands were visualized using an
Odyssey CLx Infrared Imaging System (LI-COR Biosciences)
and quantified with Image Studio software (LI-COR
Biosciences).
For Western blot analysis of A oligomers (Fig. 1F), PBS or
Neurobasal medium containing 0.5 g of A in 1 NuPAGE
lithium dodecyl sulfate sample buffer was loaded per gel lane.
A samples were electrophoresed on a 10–20% Criterion Tris-
Tricine gel (Bio-Rad, 3450068) in 2 XTMES Running Buffer
(Bio-Rad, 1610789) at 150 V for 3 h at 4 °C. Gels were trans-
ferred to nitrocellulose membranes in 1 NuPAGE transfer
buffer (LifeTechnologies,NP0006-1) containing 10%methanol
at 0.3 A for 2 h at 4 °C.Membranes were thenmicrowaved for 5
min in PBS for antigen retrieval, blocked in 5% BSA (Sigma-
Aldrich, A3803-100G) in TBS overnight at 4 °C, and incubated
with a combination of two anti-A antibodies (82E1 from IBL
America (10323) at 1:1000 dilution and 6E10 from Covance
(SIG-39320) at 1:2000 dilution) in TBS containing 5% BSA for
2 h at room temperature. Membranes were then washed with
TBST four times for 5 min at room temperature and incubated
with goat anti-mouse secondary antibodies conjugated to
IRDye (0.1 g/ml) for 1 h at room temperature followed by
washes in TBST (4  5 min). Protein bands were visualized
using an Odyssey CLx Infrared Imaging System and quantified
with Image Studio software.
Generation of EphB2DeletionMutants—Deletionmutants of
EphB2 with two FLAG tags inserted at the N-terminal side of
the ligand-binding domainwere generated using aQuikChange
II XL site-directed mutagenesis kit (Agilent Technologies,
200522). FLAG-tagged EphB2 in pFUW plasmid (32) was used
as a template in combination with the set of primers listed in
Table 2. After mutagenesis, full sequences of deletion mutants
were verified. Plasmids carrying the desired mutations were
used to transform the Stbl3 Escherichia coli strain (Life Tech-
nologies, C7373-03) for maintenance.
Production and Purification of Lentiviral Particles—Lentivi-
ral particles were generated by co-transfecting the transfer vec-
tor (pFUW with wild-type or mutant EphB2 cDNA insertion),
theHIV-1 packaging vector (Delta8.9), and the VSVG envelope
glycoprotein expression vector (pVSVG) into HEK293T cells.
Confluent HEK293T cells were transfected with three vectors
(22.5 g of pFUW, 16.9 g of Delta8.9, and 11.25 g of pVSVG
per 15-cm Petri dish) using CalPhos transfection reagent
(Clontech, 631312) according to the manufacturer’s instruc-
tion. Medium containing lentiviral particles was collected 48 h
after transfection and filtered through a 0.22-m cellulose ace-
tate filter (Corning Inc., 431154). Lentiviral particles in the
medium were then concentrated by serial ultracentrifugation:
21,000 rpm for 2 h at 4 °C in a Beckman SW28 and then 25,000
rpm for 2 h at 4 °C in a Beckman SW55 with a sucrose cushion
(2 ml of 20% sucrose in Hanks’ balanced salt solution (Life
Technologies, 14170) at the bottom of the SW55 tubes). Final
pellets were dissolved in Hanks’ balanced salt solution, ali-
quoted, and stored at 80 °C until use. Lentiviral titers were
determined with a p24 ELISA by Dr. David Chung (University
of California, San Francisco). Primary cultured hippocampal
neurons were transduced with lentiviral particles encoding
EphB2 at 0.02 pg of p24/neuron. Lentiviral vectors encoding
shRNA against GluN1 (sh-GluN1) or EphA2 were purchased
from Sigma-Aldrich or GeneCopoeia, Inc., respectively. Pri-
mary cultured hippocampal neurons were transduced with
these lentiviral particles at a multiplicity of infection of 2.
We first compared the efficacies of five sh-GluN1 lentiviruses
(Mission lentiviral transduction particles; clone IDs
TRCN0000233326, TRCN0000233327, TRCN0000233328,
TRCN0000233329, and TRCN0000257394) and selected two
equally effective sh-GluN1 constructs (TRCN0000233326 and
TRCN0000257394) for subsequent experiments. Because the
results obtained with these two lentiviruses were similar (data
not shown), theywere combined for statistical analysis and data
presentation.
Proximity Ligation Assay (PLA)—At DIV 7, primary hip-
pocampal neuronal cultures from wild-type P0-P1 pups (106
neurons plated on 12-mm poly-D-lysine/laminin-coated glass
coverslips (BD Biosciences, 354087)) were transfected with
empty pFUW plasmid or plasmids encoding EphB2WT or
EphB2PDZ. GFP-encoding plasmid was co-transfected to visu-
alize transfected neurons. To prepare the transfection mixture,
pairs of plasmids (1.0g/coverslip each) were dissolved in 50l
ofOpti-MEM(LifeTechnologies, 31985-062),mixedwith 50l
of Opti-MEM containing 1.35 l of Lipofectamine 2000 (Life
Technologies, 11668-027), and incubated for 20 min at room
temperature. The transfection mixture was added to neuronal
cultures that had been incubated inNeurobasal Amediumcon-
taining kynurenic acid (1 mM; Sigma-Aldrich, K3375-5G) and
GlutaMAX (0.5 mM; Life Technologies, 35050-061) at 37 °C
TABLE 1
Primary antibodies used for Western blotting
Antibody Source
Final
concentration
III-tubulin Sigma-Aldrich, T5076-200UL 0.1 g/ml
EphA2 Millipore, 05-480 0.2 g/ml
EphB2 R&D Systems, AF467 0.1 g/ml
ERK (phosphorylated) Cell Signaling Technology, 9101 1:2000
ERK (total) Cell Signaling Technology, 9102 1:1000
FLAG Sigma-Aldrich, F1804 2.0 g/ml
GluA2 NeuroMab, clone L21/32 0.1 g/ml
GluN1 Millipore, AB9864R 0.1 g/ml
TABLE 2
Primers used to generate deletion mutants of FLAG-tagged EphB2
s, sense; as, antisense.
Primer ID Sequence
K661R_as 5-atcctgacttgagggtcctgatggctacaaagatc-3
K661R_s 5-gatctttgtagccatcaggaccctcaagtcaggat-3
FN_as 5-actcggcttctgtcatgatggttgtgcaaggc-3
FN_s 5-gccttgcacaaccatcatgacagaagccgagt-3
LB_as 5-gaagatggcaccattcacggcggctagcag-3
LB_s 5-ctgctagccgccgtgaatggtgccatcttc-3
PDZ_as 5-gatgaaccagatccagtgacggaccggttacc-3
PDZ_s 5-ggtaaccggtccgtcactggatctggttcatc-3
SAM_as 5-gactggatctggttcatgtagtccggtatcgtgc-3
SAM_s 5-gcacgataccggactacatgaaccagatccagtc-3
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with 5%CO2 for 30–60min. Neuronal cultures were incubated
in the same transfection mixture for another 30 min at 37 °C
with 5% CO2. Cultures were then washed with prewarmed PBS
once and placed back into presaved conditioned medium. PLA
was performed according to the protocol of Duolink In Situ/
Fluorescence (Sigma-Aldrich) 1 week after transfection (at DIV
14). Neurons were fixedwith 4% paraformaldehyde, 4% sucrose
in 1 PBS for 15 min at room temperature, washed with 1
PBS (3 5 min), permeabilized with 0.2% Triton X-100 in 1
PBS for 5min, and then blockedwith 5% normal donkey serum,
1 PBS for 30 min at room temperature. They were then incu-
bated with primary antibodies (goat anti-EphB2 at 0.4 g/ml
and mouse anti-GluA2 at 0.4 g/ml) in 1% normal donkey
serum, 1 PBS at 4 °C overnight. After washing with 1 PBS
(3  5 min), neurons were incubated with two PLA probes
(Duolink In Situ PLA Probes Anti-Goat PLUS DUO92003 and
Anti-MouseMINUSDUO92004, Sigma-Aldrich) in 1% normal
donkey serum, 1 PBS for 1 h at 37 °C followed by a wash with
1Wash Buffer A (2 5 min; Sigma-Aldrich, DUO82049-4L)
and incubation in ligation solution (Sigma-Aldrich, Duolink In
Situ Detection Reagents Red, DUO92008) for 1 h at 37 °C to
ligate complimentary PLA probes that were in close (	40-nm)
proximity (38). After ligation, neurons were washed with 1
Wash Buffer A (2 2 min) and incubated in the amplification
solution (Duolink In Situ Detection Reagents Red) for 100 min
at 37 °C to fluorescently label the ligated PLA probes. Neurons
were then serially washed in 1Wash Buffer B (2  10 min;
Sigma-Aldrich, DUO82049-4L), 0.01 Wash Buffer B (1  1
min), and 1 PBS (1  5 min) followed by incubation with
secondary antibodies (Alexa Fluor 647 donkey anti-goat,
A21447 or Alexa Fluor 647 donkey anti-mouse, A-31571; Life
Technologies) in 1% normal donkey serum, 1 PBS for 1 h at
room temperature. Finally, neurons were washed with 1 PBS
(3 5min) andmounted inDuolink In SituMountingMedium
with DAPI (Sigma-Aldrich, DUO82040). Fluorescence images
were obtainedwith an epifluorescencemicroscope (NikonTi-E
microscope, Nikon Imaging Center at University of California,
San Francisco). Fluorescence intensity of the PLA signal in cell
bodies (excluding the nucleus), EphB2 or GluA2 immunofluo-
rescence, and GFP fluorescence were quantified using NIS Ele-
ments software (Nikon).
Transient Transfections—HEK293T cells were transfected
with plasmids using Lipofectamine 2000 according to theman-
ufacturer’s instructions. To prepare the transfection mixture,
plasmids encoding EphB2WT, EphB2K661R, or GluN2B (2.0
g/well each) were dissolved in 100 l of Opti-MEM, mixed
with 100 l of Opti-MEM containing 3 l of Lipofectamine
2000, and incubated for 20 min at room temperature. The
transfection mixture was then added to semiconfluent
HEK293T cells plated on 12-well plates in DMEMhigh glucose
(Life Technologies, 11965-092) supplemented with 2.4 mM
L-glutamine, and 100 units/ml penicillin/streptomycin. Cells
were used for experiments 24 h later.
Preclustering of Recombinant Fc-EphrinB2—Before addition
toHEK293Tcells expressing EphB2, recombinant Fc-EphrinB2
(5 g/ml; R&D Systems, 496-EB-200), a fusion protein of
mouse EphrinB2 and human IgG1 (39), was preclustered with
goat anti-human antibody (0.5 g/ml; Jackson ImmunoRe-
search Laboratories, 109-001-008) in serum-freeDMEMfor 1 h
on a shaker at room temperature. Preclustered Fc-EphrinB2
was diluted 1:10 and applied to HEK293T cells for 1 h at 37 °C.
Other Compounds Used—Tetrodotoxin (TTX) (catalogue
number 1078), DL-2-amino-5-phosphonovaleric acid (0105),
cyclosporin A (1101), FK506 (3631), and -bungarotoxin
(2133) were purchased from Tocris Bioscience and used as
described in the text.
Statistical Analysis—Experimenters were blinded with
respect to the genotype and treatment of cell cultures. Biologi-
cal units were randomized during assays, sampling, and analy-
ses. Statistical analyses were performed with Prism (version 6,
GraphPad) and R (R Development Core Team). Individual cul-
turewells (Western blot data) or individual transfected neurons
(PLA data) were treated as independent biological units (n).
Differences between genotypes and treatments were assessed,
as appropriate, by unpaired Student’s t test with Welch’s cor-
rection or by one-way or two-way ANOVA with Bonferroni
multiple comparison post hoc test. The null hypothesis was
rejected at p 	 0.05. In all figures, quantitative data are pre-
sented as means
 S.E.
Results
A Oligomers Deplete NMDARs and EphB2 from the Neuro-
nal Surface through Independent Mechanisms—Two-hour
treatment of primary hippocampal neuronal cultures with
recombinant A oligomers (2 M; monomer equivalent)
reduced levels of surface GluN1 (sGluN1) (Fig. 1A), an obliga-
tory subunit of NMDARs, consistent with previous reports (7,
10). At this time point, levels of surface EphB2 (sEphB2) were
still unchanged (Fig. 1A). Reductions of sEphB2 levels were
observed after 48 h of A treatment (Fig. 1B), consistent with
previous findings (12, 32). Notably, 2-h treatment with A olig-
omers reduced sGluN1 levels also in primary hippocampal neu-
rons from mice lacking EphB2 (Fig. 1C). Thus, at least in these
mouse cultures, A-induced depletion of sGluN1 does not
depend on EphB2 or alterations in its surface levels.
We confirmed the oligomeric nature of the recombinant A
preparations used in these experiments by atomic forcemicros-
copy (Fig. 1D). We also removed medium from neuronal cul-
tures 2 and 48 h after addition of A oligomers and character-
ized the A species they contained by Western blot analysis as
well as by SEC and ELISA (Fig. 1, E and F). The medium con-
tained higher levels of A oligomers at 2 h than at 48 h after
addition of A oligomers (Fig. 1, E and F), possibly because,
with time, more and more A oligomers bind to neuronal sur-
face membranes (40) and are sequestered by the formation of
A fibrils. Western blot analysis revealed putative A oligo-
mers even in preparations of freshly solubilized A peptides
(Fig. 1F), likely due in part to the fact that SDS promotes the
oligomerization of A(1–42) in gels (41).
In light of the known interactions between NMDARs and
EphB2 (33), we next examined whether depletion of NMDARs
may underlie the subsequent depletion of sEphB2. We first
examined whether known inhibitors of A-induced sGluN1
depletion block the subsequent depletion of sEphB2. -Bunga-
rotoxin (BTX), a blocker of -7 nicotinic acetylcholine recep-
tors (-7), has been reported to partially block A-induced
EphB2 PDZ Interactions Block NMDA Receptor Depletion by A
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sGluN1 depletion (7). Two antagonists of the protein phospha-
tase calcineurin, FK506 and cyclosporin A, were also reported
to blockA-induced sGluN1depletion (7) and synaptic depres-
sion (9). However, treatment of neuronal cultures with BTX (10
M) or FK506 (50M) did not prevent A-induced depletion of
sGluN1 (Fig. 2,A–C). Cyclosporin A (20M) increased sGluN1
levels and counteracted A-induced sGluN1 depletion at 2 h
(Fig. 2, D–F). However, 48-h treatment with cyclosporin A
actually exacerbated the A-induced depletion of sGluN1 and
sEphB2 (Fig. 2, G–J).
To evaluate the dependence of sEphB2 levels on sGluN1 lev-
elsmore directly, we transduced neurons with lentiviral vectors
expressing an anti-GluN1 short hairpin RNA (sh-GluN1) or a
scrambled shRNA (sh-SCR). Transducing neurons with lenti-
virus encoding sh-GluN1 depleted both total and surface levels
of GluN1moremarkedly and formuch longer (DIV 2–14) than
the 2-h A exposure, but it had no effect on levels of total or
surface EphB2 (Fig. 3A and data not shown). These results sug-
gest that depletion of sGluN1 is not sufficient to lower sEphB2
levels and that A oligomers may deplete sGluN1 and sEphB2
through parallel mechanisms.
Because NMDAR activity is required for A oligomers to
impair neuronal functions (42), we also examined whether
blocking NMDAR activity attenuates A-induced sEphB2
depletion. Treatment of neuronal cultures with the NMDAR
antagonist AP5 (100 M) had no effect on A-induced sEphB2
depletion (Fig. 3B), suggesting that theA-induced depletion of
sEphB2 does not require NMDAR activity.
A-induced Depletion of sGluN1 and sEphB2 Does Not
Require Tau, PrPC, or Neuronal Activity—Wenext investigated
whether potential mediators of A-induced neuronal impair-
ments, specifically tau, PrPC, and aberrant excitatory neuronal
FIGURE 1. A-induced depletion of surface GluN1 in primary neuronal cultures precedes and does not depend on depletion of surface EphB2. A–C,
culturesof primaryhippocampal neurons (DIV10–14) fromwild-type (A–C) and Ephb2/ (C)micewere treatedwithAoligomers (2M)or vehicle (Veh; 0.08%
DMSO) and then analyzed for surface (s) and total (t) levels of GluN1 and EphB2 byWestern blotting.III-tubulin was used as a loading control for total protein
levels. Representative Western blots are shown on the left, and quantitations of Western blot signals are shown on the right. Protein levels in vehicle-treated
wild-type neurons were arbitrarily defined as 1.0. A, sGluN1, but not sEphB2, levels were reduced after 2 h of A exposure. n 26–30wells per condition from
eight independent experiments. B, sEphB2 levels were reduced after 48 h of A exposure. n 12 wells per condition from four independent experiments. C,
2 h of A exposure reduced sGluN1 levels inwild-type and EphB2-deficient neurons.n 23–24wells per condition from four to five independent experiments.
D–F, Aoligomerswere characterizedbyAFM (D), ELISAonSEC fractions (E), andWesternblot analysis (F).D, AFM imagesofA(1–42) peptidesbefore (left) and
after (middle) oligomerization and of a vehicle control (right). Note the globular bright structures representing putative A oligomers in the middle panel. E,
mediumremoved fromneuronal cultures 2 (black) or 48 (white) h after additionofAoligomerswere fractionatedbySEC, andA(1–42) concentrations in each
fractionwere determined by ELISA. Arrows indicate the relation of fractions to themolecular weight of eluted peptide assemblies. F, preparations of A(1–42)
peptides before (Pre) and after (Post) oligomerization andmedium removed from neuronal cultures 2 or 48 h after addition of A oligomers were analyzed by
Western blotting using a combination of anti-A antibodies 82E1 and 6E10. Molecular massmarkers (kDa) are indicated on the left. **, p	 0.01; ***, p	 0.001
versus vehicle (unpaired t test with Welch’s correction). Bars and error bars represent means and S.E., respectively.
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activity (15–17, 19–21, 23–27), are required for A-induced
depletion of sGluN1 and sEphB2. Treatment with A oligo-
mers depleted sGluN1 (Fig. 4,A–F) and sEphB2 (Fig. 5,A–F) in
primary hippocampal neurons from mice lacking tau or PrPC
and in wild-type neurons treated with TTX, which blocks
action potentials by inhibiting voltage-gated sodium channels.
The extent of A-induced sGluN1 and sEphB2 depletion in
PrPC-deficient (Figs. 4, A and B, and 5, A and B), tau-deficient
(Figs. 4, A and B, and 5, A and B), and TTX-treated wild-type
(Figs. 4,D and E, and 5,D and E) cultures was comparable with
that in wild-type control cultures (Fig. 1, A and B). To confirm
that TTX was effective in these experiments, we measured lev-
els of phosphorylated (i.e. activated) ERK, which TTX reduced
(Figs. 4G and 5G). Thus, tau, PrPC, and aberrant excitatory neu-
ronal activity are unlikely mediators of the A-induced deple-
tion of sGluN1 and sEphB2, at least in these culture models.
Ability of EphB2 to Prevent A-induced Depletion of sGluN1
Depends on Its PDZ-bindingMotif—Wepreviously showed that
normalizing EphB2 levels in the dentate gyrus of hAPP trans-
genic mice reversed deficits in NMDAR function (32), and oth-
ers recently showed that EphB2 overexpression also counter-
acts A-induced NMDAR dysfunctions in neuronal cultures
(43). Overexpression of FLAG-tagged wild-type EphB2
(EphB2WT) also prevented A-induced depletion of sGluN1 in
neuronal cultures in the current study (Fig. 6). In one experi-
ment, increasing the expression of EphB2WT in primary cul-
tures of rat hippocampal neurons also partially counteracted
the depletion of sGluN1 caused by synthetic A oligomers,
FIGURE 2. A-induced depletion of sGluN1 occurs in the presence of -bungarotoxin, FK506, or cyclosporin A. A–C, cultures of primary hippocampal
neurons (DIV 12–14) from wild-type mice were treated with A oligomers (2 M) or vehicle (Veh; 0.08% DMSO) for 2 h followed by Western blot analysis of
sGluN1 and tGluN1. Some cultures were treated with BTX (10 M) or FK506 (50 M) from 30 min before until the end of exposure to A or vehicle. A,
representative Western blots. B and C, quantitation of sGluN1 (B) and tGluN1 (C) levels. n  8 wells per condition from two independent experiments. D--I,
cultures of primary hippocampal neurons (DIV 12) fromwild-type mice were treated with A oligomers (2 M) or vehicle (Veh; 0.08% DMSO) for 2 (D--F) or 48
(G–J) h followed byWestern blot analysis of surface (s) and total (t) levels of GluN1 and EphB2. Some cultures were treated with cyclosporin A (CS; 20M) from
30 min before until the end of exposure to A or vehicle. D and G, representative Western blot. E and F, quantitations of sGluN1 (E) and tGluN1 (F) levels. n
6 wells per condition from one experiment. H–J, quantitations of sGluN1 (H), sEphB2 (I), and tEphB2 (J) levels. n 6 wells per condition from one experiment.
Two-way ANOVA revealed a significant interaction between A oligomers and compounds in E (p	 0.001); a significant effect of A oligomers in B, E, H, and
I (p	 0.0001); and significant effects of compounds in B (p	 0.05), E (p	 0.0001), H (p	 0.0001), and I (p	 0.0001). There were no significant interactions
betweenAoligomers and compounds in B,H, and I. *, p	 0.05; **, p	 0.01; ****, p	 0.0001 versus vehicle or as indicatedby bracket in E (Bonferroni test). Bars
and error bars represent means and S.E., respectively.
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which, by Western blot analysis, contained more putative
higher order assemblies than recombinant A oligomers (data
not shown).
To begin to explore the molecular mechanism by which
EphB2 exerts this protective effect, we generated multiple con-
structs encoding mutant forms of FLAG-tagged EphB2 (Fig. 6,
A–C), including EphB2 lacking the ligand-binding domain
(EphB2LB), the fibronectin repeats (EphB2FN), the SAM
domain (EphB2SAM), the PDZ-binding motif (EphB2PDZ), or
kinase activity (EphB2K661R). Western blot analyses of wild-
type neuronal cultures transduced with the different EphB2
constructs confirmed the expected changes in molecular
weight and interaction with the anti-FLAG antibody (Fig. 6B).
Although the EphB2 antibody used in this study is polyclonal
and recognized all EphB2mutants we generated, it showed rel-
atively less reactivity with EphB2FN, which was recognized
readily by the anti-FLAG antibody (Fig. 6B). Kinase-deficient
EphB2K661R in which the lysine 661 residue critical for tyrosine
kinase activity was mutated to arginine failed to mediate eph-
rinB2-induced phosphorylation of the tyrosine 1472 residue
(Tyr-1472) onGluN2B (Fig. 6C), confirming the desired impact
of the mutation.
Except for EphB2PDZ, all EphB2mutants andEphB2WTpre-
vented A-induced sGluN1 depletion when overexpressed in
primary cultures of hippocampal neurons (Fig. 6D). As docu-
mented in Figs. 1C and 6D (Empty), the endogenous EphB2,
whichwas coexpressed in these cultures, would not be expected
to modulate the A-induced depletion of sGluN1. It is also
worth noting that deletion of the PDZ-binding motif did not
alter cell surface expression, localization in spines, and ephrin-
dependent clustering of FLAG-tagged EphB2 (44), suggesting
that the lack of protective effect by EphB2PDZ was not caused
by alterations in its subcellular localization.
Over the time frame of this experiment, levels of total GluN1
were not significantly altered by treatment with A oligomers
or expression of EphB2 (Fig. 6E). The degree of EphB2 overex-
pression we achieved by lentiviral transduction of neurons was
variable across constructs as determined byWestern blot anal-
ysis of neuronal lysates (Fig. 6, F and G), possibly reflecting
differences in the reactivity of EphB2 mutants with the anti-
EphB2 antibody or in their stability. For most constructs, levels
of sEphB2 correlated well with those of total EphB2 (tEphB2);
however, sEphB2LB levels were low despite high levels of
tEphB2LB expression (Fig. 6, F and G). Surface levels of
EphB2LB and likely EphB2FN may have appeared lower than
they actually were because these constructs lack large portions
of the extracellular part of the molecule (Fig. 6A) and thus
might have been less efficiently biotinylated and/or pulled
down. Regardless, these two EphB2mutants were able to coun-
teract A-induced sGluN1 depletion.
Notably, overexpressing EphB2 did not prevent A-induced
GluN1 depletion when neuronal cultures were treated with
TTX (Fig. 7, A and B), suggesting that neuronal activity is
required for EphB2 overexpression to counteract this A effect.
Treatment of cultures with A oligomers or TTX and overex-
pression of EphB2WT did not significantly alter total GluN1
levels (Fig. 7,A andC). Independently of whether cultures were
treated with A oligomers, TTX, or both, overexpression of
EphB2WT increased levels of total EphB2 and sEphB2 roughly
4–6-fold over endogenous EphB2 levels found in cultures
transduced with control virus (Fig. 7, A, D, and E). We again
confirmed the efficacy of TTX in this experiment by monitor-
ing phospho-ERK levels (Fig. 7, A and F).
Ability of EphB2 to Counteract the Effect of A Oligomers
May Depend on Its Interaction with GluA2—EphB2 can phos-
phorylateNMDARs through its tyrosine kinase activity and can
directly bind to them via its extracellular domains (33). How-
ever, overexpression of EphB2 mutants lacking kinase activity
or specific extracellular domains still prevented A-induced
depletion of surface GluN1, which makes it unlikely that the
protective ability of EphB2 is mediated by direct effects on
NMDARs. Therefore, we focused onGluA2, which can become
indirectly associated with the PDZ-binding motif of EphB2
through direct interactions with PDZ domain-containing pro-
teins (44, 45). Additionally, endocytosis ofGluA2 is required for
A to depress NMDAR currents and synaptic function (9).
FIGURE 3.Depleting or blocking NMDARs does not affect EphB2 levels in
cultured neurons. A, cultures of primary hippocampal neurons (DIV 2) from
wild-type mice were not transduced (No Virus) or transduced with lentivirus
(multiplicity of infection of 2) encoding scrambled shRNA (sh-SCR) or shRNA
against GluN1 (sh-GluN1) followed by Western blot analysis of GluN1 and
EphB2 levels atDIV14. Cultureswerenot treatedwithA.n10–26wells per
condition from two independent experiments. B, cultures of primary hip-
pocampal neurons (DIV 10–14) from wild-type mice were treated for 48 h
with A oligomers (2M) or vehicle (Veh; 0.08%DMSO) in the presence of the
NMDAR antagonist AP5 (100M) or vehicle (0.1%water) followedbyWestern
blot analysis of sEphB2 levels. RepresentativeWestern blots are shownon the
left, and quantitations of Western blot signals are shown on the right. n 9
wells per condition from two independent experiments. Two-way ANOVA
revealed no significant interaction between the effects of A and AP5 on
sEphB2 levels. **, p 	 0.01; ***, p 	 0.001 versus sh-SCR (A) or vehicle (B) by
Bonferroni test. Bars and error bars represent means and S.E., respectively.
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FIGURE 4. A-induced depletion of sGluN1 occurs in the absence of tau, PrPC, or neuronal activity. A–C, cultures of primary hippocampal neurons (DIV
10–14) from tau-deficient (Mapt/) or PrPC-deficient (Prnp/) mice were treatedwith A oligomers (2M) or vehicle (Veh; 0.08%DMSO) for 2 h followed by
Western blot analysis of sGluN1 and tGluN1 levels. A, representativeWestern blots. The red bar represents the boundary between differentmembranes. B and
C, quantitation of sGluN1 (B) and tGluN1 (C) levels.n 12–14wells per condition from three to four independent experiments. The degree of sGluN1depletion
in these cultureswas comparablewith that in control wild-type hippocampal cultures assessed in side-by-side experiments (data not shown).D--G, cultures of
primary hippocampal neurons (DIV 10–14) fromwild-typemicewere treatedwith A oligomers or vehicle for 2 h followed byWestern blot analysis of sGluN1,
tGluN1, phosphorylated (p) ERK, and total (t) ERK levels. Some cultures were treated with TTX (1M) 30min before and throughout exposure to A or vehicle.
Phospho-ERK levelswerenormalized to total ERK levels.D, representativeWesternblot.E–G, quantitationsof sGluN1 (E), tGluN1 (F), andphospho-ERK (G) levels.
For ERK levels, the sumof twobands (ERK1 and -2)was quantitated. n 16wells per condition from four independent experiments. Two-wayANOVA revealed
an interaction between the effects of A and TTX on phospho-ERK levels (p	 0.05) but not on sGluN1 levels (p 0.98). One-way ANOVA revealed a significant
(p	 0.001) TTX effect on phospho-ERK levels. *, p	 0.05; **, p	 0.01 versus vehicle by unpaired t testwithWelch’s correction (B) or Bonferroni test (E). Bars and
error bars represent means and S.E., respectively.
FIGURE 5. A-induced depletion of sEphB2 occurs in the absence of tau, PrPC, or neuronal activity. A–C, cultures of primary hippocampal neurons (DIV
10–14) from tau-deficient (Mapt/) or PrPC-deficient (Prnp/)micewere treatedwith Aoligomers (2M) or vehicle (Veh; 0.08%DMSO) for 48 h followedby
Western blot analysis of sEphB2 and tEphB2 levels. A, representativeWestern blots. The red bar represents the boundary between differentmembranes. B and
C, quantitation of sEphB2 (B) and tEphB2 (C) levels. n  12–18 wells per condition from three to four independent experiments. D--G, cultures of primary
hippocampal neurons (DIV 10–14) fromwild-typemicewere treatedwithAoligomers or vehicle for 48h followedbyWesternblot analysis of sEphB2, tEphB2,
phosphorylated (p) ERK and total (t) ERK levels. Some cultures were treated with TTX (1 M) from 30 min before until the end of exposure to A or vehicle. D,
representative Western blot. E–G, quantitations of sGluN1 (E), tGluN1 (F), and phospho-ERK (G) levels. n  12 wells per condition from three independent
experiments. **, p	 0.01; ***, p	 0.001 versus vehicle by unpaired t test with Welch’s correction (B) or Bonferroni test (E and G). Bars and error bars represent
means and S.E., respectively.
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Treatment of neuronal cultures with A oligomers
decreased surface levels of the AMPAR subunit GluA2 (Fig.
8A), consistent with previous reports (9, 13, 14). sGluA2 was
depleted by Awithin 2 h, which is similar in time frame to the
depletion of sGluN1 and much faster than the depletion of
sEphB2. Interestingly, EphB2 overexpression counteracted the
A-induced depletion of sGluA2 through a mechanism that
depended on the presence of the PDZ-binding motif of EphB2
(Fig. 8A). To monitor interactions between EphB2 and GluA2
in primary neuronal cultures, we used a PLA that allows for the
in situ detection of two antigens only when they are in close
proximity (	40 nm) (38).
At comparable levels of overexpression, EphB2WT showed
more colocalization with GluA2 than EphB2PDZ indepen-
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dently of whether cultures were treated with vehicle or A (Fig.
8, B–F). Treatment with A oligomers reduced the colocaliza-
tion of EphB2 and GluA2 in neurons overexpressing EphB2WT
or EphB2PDZ (p	 0.01 by two-way ANOVA). TTX treatment
hadno effect on colocalization betweenGluA2 and endogenous
EphB2 or overexpressed EphB2WT but increased colocalization
between GluA2 and overexpressed EphB2PDZ (Fig. 8F), possi-
bly due to increased surfaceGluA2 resulting from synaptic scal-
ing (46). For unclear reasons, TTX treatment reduced the levels
of overexpressed EphB2WT but not EphB2PDZ (Fig. 8D). This
difference may have obscured some effects of the mutation, for
example, resulting in the detection of comparable levels of
interaction betweenGluA2 and EphB2WT versus EphB2PDZ in
the presence of TTX (Fig. 8F). GluA2 levels were not altered by
overexpression of EphB2WT or EphB2PDZ under control con-
ditions (Fig. 8E). GluA2 levels were reduced by A in neurons
that were transfected with empty vector or vector encoding
EphB2PDZ but not in those overexpressing EphB2WT (Fig. 8E).
Taken together, these results suggest that EphB2 overexpres-
sion may counteract A-induced depletion of sGluN1 by
increasing sGluA2 levels.
Lastly, we tested and refuted the hypothesis that overexpres-
sion of any protein bearing a PDZ-bindingmotif can counteract
the effect of A oligomers on cell surface glutamate receptors.
For this purpose, we focused on EphA2, another receptor tyro-
sine kinase with a PDZ-binding motif (47). To our knowledge,
EphA2 has not been demonstrated to interact with or regulate
glutamate receptors.Overexpression of EphA2 in culturedneu-
rons did not prevent A-induced depletion of sGluN1 (Fig. 9).
Discussion
This study demonstrates that the ability of EphB2 to coun-
teract A-induced depletions of AMPARs and NMDARs
depends on its PDZ-bindingmotif and the presence of neuronal
activity. We also obtained evidence suggesting that this effect
may involve interactions between the PDZ-binding motif of
EphB2 and GluA2, which could promote the retention of
GluA2 at the surface membrane and prevent A-induced
depletion of surface NMDARs (9, 14). From a therapeutic per-
spective, it is important to note that these protective EphB2
effects were observed only when EphB2 was expressed at sup-
raphysiological levels and that they did not depend on its kinase
activity.
We also found that A-induced depletions of NMDARs do
not depend on EphB2 depletion, tau, PrPC, or aberrant neuro-
nal activity, all of which have been implicated in A-induced
neuronal dysfunction (12, 15–17, 20, 21, 23–27, 31, 32, 43). One
interpretation of these findings is that NMDAR depletion
occurs upstream of the other factors within the pathogenic cas-
cade that A oligomers trigger. However, we found that A
oligomers depleted EphB2 even in the presence of cyclosporin
or AP5, which prevented A-induced depletion of NMDARs.
An alternative possibility is that A oligomers activate parallel
pathways that affect neuronal functions through distinct
mechanisms.
It should be noted in this context that all our findings were
obtained in dissociated primary neuronal cultures. We cannot
exclude the possibility that the relationships among the factors
we studied are different in vivo. As is true for most data
obtained in experimental models, the relevance of our findings
to patients with AD also remains uncertain and deserves to be
further explored in future studies. Notwithstanding these cave-
ats, the novel mechanistic insights our study provides could
guide the development of strategies to counteract A-induced
neuronal dysfunction and help make the brain more resistant
against pathogenic A assemblies.
A oligomers deplete and dysregulate glutamate receptors
and relatedmolecules, including EphB2 (7, 9–12, 14, 32). How-
ever, it has remained uncertain whether these alterations are
causally linked with each other and, if so, in which sequence or
constellation. Our results suggest that A-induced endocytosis
of GluA2 acts upstream of and may promote the depletion of
GluN1, consistent with previous studies showing that GluA2
endocytosis is required for A-induced NMDAR dysfunction
and synaptic depression (9, 14). Interestingly, the A-induced
depletions of GluA2 and GluN1 could be prevented by neuro-
nal overexpression of EphB2WT but not EphB2PDZ. EphB2
FIGURE 6. Prevention of A-induced GluN1 depletion by overexpression of EphB2 depends on PDZ-binding motif of EphB2. A, schematic diagram of
FLAG-tagged mouse EphB2 showing functionally important domains and amino acid residues. The last four amino acids in the C terminus (SVEV; the PDZ-
binding motif) are critical for binding to PDZ domain-containing proteins. Lysine 661 (K661) is critical for kinase activity of EphB2. B, expression of different
EphB2 constructs in primary neurons. Cultures of hippocampal neurons (DIV 2) from wild-type mice were transduced (0.02 pg of p24/neuron) with empty
lentivirus (Empty) or with lentivirus encoding EphB2WT (WT), EphB2LB (LB), EphB2FN (FN), EphB2K661R (K661R), EphB2SAM (SAM), or EphB2PDZ (PDZ)
followed by Western blot analysis for EphB2 and FLAG on DIV 14. Except for EphB2LB, all constructs contained a FLAG tag at the N-terminal side of the
ligand-binding domain (A). The sameWestern blotwas probedwith a polyclonal anti-EphB2 antibody (top) and amonoclonal anti-FLAG antibody (middle) and
labeled with secondary antibodies conjugated to distinct fluorophores. Wild-type and mutant EphB2 bands are indicated by black and red arrowheads,
respectively. The faint bands between 75 and 100 kDa in the EphB2 blot are probably nonspecific as they were also present in primary neurons from
EphB2-deficient mice (data not shown). C, substitution of Lys-661 for arginine (K661R) specifically disrupts the kinase activity of EphB2. HEK293T cells were
transiently transfectedwithplasmids encodingEphB2WTorGluN2Bor co-transfectedwithGluN2Bplus EphB2WTor EphB2K661R. Twodays after the transfection,
cells were treated for 1 h at 37 °C with preclustered human Fc-EphrinB2 (500 ng/ml) followed byWestern blot analysis for GluN2B, GluN2B phosphorylated at
tyrosine 1472 (GluN2Bp1472), EphB2, and-tubulin.D--G, cultures of primary hippocampal neurons (DIV 2) fromwild-typemice were transducedwith different
EphB2constructs as inB. AtDIV12–14, neuronswere treatedwithAoligomers (2M)or vehicle (Veh; 0.08%DMSO) for 2h followedbyquantificationof sGluN1
(D), tGluN1 (E), tEphB2 (F), and sEphB2 (G) levels byWesternblot analysis. RepresentativeWesternblots are shownon the left, andquantitations ofWesternblot
signals are shown on the right. The red bars represent the boundary between differentmembranes. Two representativeWestern blots with duplicate samples
for someEphB2constructs are shown.n15–33wells per condition from four tonine independent experiments. InD, overexpressionof eachEphB2construct,
except for EphB2PDZ, prevented the A-induced depletion of sGluN1. In E and F, theIII-tubulin blots are the same. In F andG, bands of EphB2WT, EphB2K661R,
EphB2SAM, and EphB2PDZ overlapwith that of endogenous EphB2 at120 kDa,whereas bands of EphB2LB and EphB2FN reside below the faint nonspecific
band around 80 kDa (see also B). Wild-type and mutant EphB2 bands are indicated by black and red arrowheads, respectively. Quantitations of EphB2 levels
represent the sum of endogenous (120 kDa) and exogenous (WT or mutant) EphB2 signals. Two-way ANOVA revealed a significant (p	 0.01) interaction
between the effects of A treatment and EphB2 transduction on sGluN1 levels (D), significant effects of EphB2 constructs (p	 0.0001) but not of A, and no
significant interaction between EphB2 constructs and A (F andG). **, p	 0.01; ***, p	 0.001; ****, p	 0.0001 versus vehicle condition (D) or empty condition
(F and G) by Bonferroni test. Bars and error bars represent means and S.E., respectively.
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regulates trafficking of GluA2 by amechanism that depends on
its PDZ-binding motif: the PDZ-binding motif of EphB2 binds
to the PDZ domain-containing scaffold protein glutamate
receptor-interacting protein 1, which binds to GluA2 and reg-
ulates the localization of GluA2-containing AMPARs (33, 44,
45). Using a PLA approach, we confirmed that this motif is
required for the association of EphB2 with GluA2.
In contrast, the PDZ-binding motif does not appear to be
involved in interactions between EphB2 and NMDARs.
Instead, EphB2 can regulate NMDAR localization and function
by directly binding to GluN1 through its extracellular domain
and phosphorylatingGluN2B through its kinase activity (33, 39,
48). However, although the kinase activity of EphB2 can influ-
ence NMDAR localization and function in vitro (39), NMDAR
impairments in EphB2-deficient mice could be normalized by
expression of kinase-deficient EphB2 (49), suggesting a more
limited or different role for this activity in vivo.
In the current study, the prevention of A-induced GluN1
depletion by overexpression of EphB2 was independent of the
kinase activity of EphB2 as well as of its ligand-binding domain
and fibronectin repeats, which together make up most of the
extracellular domain. In our view, themost parsimonious inter-
pretation of these findings is that overexpression of EphB2 pre-
vents A-induced NMDAR depletion by PDZ-binding motif-
mediated retention of GluA2 at the surface membrane, which
would be expected to counteract A-induced enhancement of
GluA2 endocytosis and consequent GluN1 depletion (9).
Because this protective effect of EphB2was observedonlywhen
itwasoverexpressedandAoligomersdepleted sGluN1to similar
degrees in wild-type and EphB2-deficient neurons, it is likely that
the association between endogenous EphB2 and GluA2 is not
strong enough to retain GluA2 at the surface, at least in the pres-
ence of pathologically elevated levels of A oligomers. However,
because genetic ablation of EphB2 during early stages of develop-
FIGURE 7.Prevention of A-inducedGluN1depletion by overexpression of EphB2depends onneuronal activity. Silencing neuronal activity by treating
neurons with TTX (1 M) for 30 min before and throughout the A exposure prevented lentivirus-mediated overexpression of EphB2WT from blocking the
A-induced depletion of sGluN1. Cultures of primary hippocampal neurons (DIV 2) fromwild-typemice were transduced (0.02 pg of p24/neuron) with empty
lentivirus (Empty) or with lentivirus encoding EphB2WT. At DIV 12–14, cultures were treated with A oligomers (2 M) or vehicle (Veh; 0.08% DMSO) for 2 h
followed by Western blot analysis. Cultures were or were not treated with TTX (1 M) 30 min before and throughout A or vehicle treatment as indicated.
Treatments are shownbelow the bar graphs; whether A oligomers or TTX () or vehicle () was applied is indicated. n 9–10wells per condition from three
independent experiments. A, representative Western blot. tERK, total ERK. B–F, quantitation of Western blot signals for sGluN1 (B), tGluN1 (C), sEphB2 (D),
tEphB2 (E), and phosphorylated (p) ERK (F). In B, two-way ANOVA revealed no significant interaction between the effects of A and TTX on sGluN1 levels in
cultures transduced with empty (p 0.49) or EphB2WT (p 0.09)-expressing lentivirus. For the empty condition in F, two-way ANOVA revealed a significant
effect of TTX (p	 0.001) and of A (p	 0.01) and significant (p	 0.01) interaction. n.s., not significantly different; **, p	 0.01; ***, p	 0.001 versus vehicle
condition or as indicated by brackets (Bonferroni test). Bars and error bars represent means and S.E., respectively.
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ment may engage compensatory mechanisms (32, 50), it remains
possible that endogenous EphB2 counteracts the A-induced
depletion of sGluN1 in wild-type neurons of the adult brain.
It is interesting that neuronal activity was required for over-
expression of EphB2 to prevent A-induced GluN1 depletion
even though neuronal activity did not influence the association
FIGURE 8. Prevention of A-inducedGluA2 depletion by overexpression of EphB2 also depends on PDZ-bindingmotif of EphB2 andmay involve interac-
tions between GluA2 and EphB2. A, overexpression of EphB2 prevents A-induced depletion of sGluA2, and this effect requires the PDZ-bindingmotif of EphB2.
Neuronswere transducedwith different EphB2 constructs and treatedwith A as described in Fig. 6,D–G, followedby quantitation of sGluA2 levels byWestern blot
analysis. Two representativeWesternblots are shownon the left, andquantitationsofWesternblot signals are shownon the right.n15–18wellsper condition from
threeto four independentexperiments.Two-wayANOVArevealedasignificant (p	0.05) interactionbetweentheeffectsofA treatmentandEphB2transductionon
sGluA2 levels. B–F, putative interactions between EphB2 andGluA2 in individual transfectedneuronsweremonitoredwith a PLA inwhich fluorescence signal above
background indicates close proximity (	40 nm) between EphB2 andGluA2. Cultures of primary hippocampal neurons (DIV 7) fromwild-typemicewere transfected
with empty pFUW plasmid (Empty) or with pFUW plasmid encoding EphB2WT or EphB2PDZ. GFP-encoding plasmid was co-transfected to visualize transfected
neurons. Some cultureswere treatedwithAoligomers (2M) or vehicle (Veh; 0.08%DMSO) for 24 h, andotherswere treatedwith TTX (1M) or vehicle for 6 h prior
to fixation. Fixed cultureswere analyzed by PLA and immunostained for EphB2 or GluA2. B, for each treatment and transfection condition, PLA signals are shownon
the left, EphB2 immunoreactivity is shown in themiddle, and GFP fluorescence is shown on the right. GFP fluorescence was observed only in transfected neurons.
EphB2 imageswerealso thresholdedto identifyprimarilyEphB2-transfectedneurons,whichdisplayedstrongerEphB2 immunoreactivity thanuntransfectedneurons
expressing only endogenous EphB2. Scale bar, 100m. C, GluA2 immunostaining for each treatment and transfection condition. Scale bar, 100m.D and E, relative
intensity of EphB2 (D) and GluA2 (E) immunofluorescence in cell bodies of GFP-positive neurons. n 16–59 neurons per condition from two independent experi-
ments. F, relative PLA signal indicating EphB2-GluA2 colocalization. EphB2-GluA2 interactions were 1) increasedwhen EphB2was overexpressed, 2) reduced by A,
and 3) partly dependent on the PDZ-binding motif of EphB2. n 51–85 neurons per condition from four independent experiments. Two-way ANOVA revealed
significanteffectsof EphB2constructs (p	0.0001),A (p	0.05), andTTX (p	0.05) andnosignificant interactionsbetweenEphB2constructs andAorTTX.n.s., not
significantly different; *, p	 0.05; **, p	 0.01; ***, p	 0.001; ****, p	 0.0001 versus vehicle (A) or versus control (Ctrl) condition or as indicated by brackets (D–F) by
Bonferroni test. Bars and error bars representmeans and S.E., respectively.
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between EphB2 andGluA2. These results suggest that neuronal
activity plays a role downstream of GluA2 engagement, possi-
bly through homeostatic synaptic scaling (46, 51).
In another potential pathway, A oligomers were proposed
to serially activate -7 and striatal enriched protein tyrosine
phosphatase (STEP61), leading to dephosphorylation of
GluN2B by STEP61 and depletion of GluN1 (7). In contrast to
results obtained by Snyder et al. (7), the-7 antagonist BTXdid
not prevent A-induced GluN1 depletion in the current study.
In both studies, high concentrations (10 M) of BTX were used
as compared with its subnanomolar IC50 (52). Therefore, vari-
able degrees of -7 blockade are unlikely to account for the
discrepancy. In a similar vein, although the calcineurin inhibi-
tors FK506 and cyclosporin A have been reported to prevent
APP/A-induced NMDAR dysfunction (7, 9), FK506 was inef-
fective in our study, and cyclosporin A prevented A-induced
GluN1 depletion during the first 2 h as reported previously (7)
but not after 48 h of A exposure. Differential effects of these
calcineurin inhibitors (53) and differences in experimental sys-
tems (organotypic slice culture versus primary neuronal culture
and APP overexpression versus exposure to recombinant
A(1–42) oligomers) may explain the different results. Nota-
bly, both genetic ablation (10) and pharmacological blockade
(7) of -7 blocked A-induced GluN1 depletion only partially.
Based on our results and those obtained by others (9), we sus-
pect that enhanced GluA2 endocytosis contributes to the
A-induced depletion of NMDARs more strongly than activa-
tion of -7 and STEP61.
Although exposure to A oligomers depleted both sEphB2
and sGluN1 and the A-induced depletion of GluN1 could be
prevented by overexpression of EphB2, the depletion of GluN1
did not depend on the depletion of EphB2, suggesting that A
oligomers deplete EphB2 and GluN1 through independent
mechanisms. Notably, the A oligomers generated from
recombinant A(1–42) in the current study depleted surface,
but not total, EphB2 even when we used them at high concen-
tration (up to 5 M) or exposed cultures to them for longer
periods (up to 6 days) (data not shown). These results are con-
sistent with those obtained in a previous study using similar A
oligomers (12) but differ from those we obtained with naturally
secreted A oligomers from 7PA2-CHO cells that depleted
both surface and total EphB2 (32). The discrepancy could be
due to differences in the A preparations used. Although
increasing the expression of EphB2 counteracted the depletion
of sGluN1 by recombinant or synthetic A oligomers that dif-
fered in their content of putative higher order assemblies, it
remains possible that overexpression of EphB2 protects against
the detrimental effects of some types of A oligomers but not
others.
Our findings that A oligomers depleted bothNMDARs and
AMPARs in neuronal cultures are consistent with those of pre-
vious studies (7, 9, 10, 12, 14, 32, 54, 55, 57). We also demon-
strated that overexpression of EphB2 rescued both types of
glutamate receptors in these culture models. In contrast, elec-
trophysiological recordings in acute hippocampal slices from
hAPP-J20 mice have so far revealed primarily deficits in the
function ofNMDARs but not of AMPARs (32, 57), and normal-
ization of neuronal EphB2 levels in the dentate gyrus of these
mice appeared to specifically rescue NMDAR function (32).
These discrepancies may be due to differences in the (a) dura-
tion of exposure to elevatedA levels (severalmonths in hAPP-
J20 mice versus 2 or 48 h in the current study), (b) APP metab-
olites (mixture of A peptides and other APP metabolites
produced by neurons in brain versus recombinant A(1–42)
added to cell culture medium), (c) cell types exposed to A
(diverse populations of mature neurons, glia, and endothelial
cells in hAPP-J20 mice versus primary cultures enriched for
young hippocampal neurons), and (d) duration and extent of
EphB2 expression (several months of normalized levels in
hAPP-J20 mice versus 10–12 days of overexpression in cul-
tured hippocampal neurons). Thus, the mechanisms by which
EphB2 normalization reversed functional deficits in hAPP-J20
mice may well have been at least partly different from those by
which EphB2 overexpression prevented depletion of surface
glutamate receptors in the current study.
Although many A-induced effects on neuronal integrity
and function depend on the presence of tau (15–17, 58–66),
others do not. In the current study, tau was not required for A
oligomers to deplete GluN1 and EphB2. Tau also does not
appear to be required for the A-induced loss of dendritic
spines (60, 67). Given the roles of GluN1 and EphB2 in the
formation and maintenance of dendritic spines (33, 68), it is
tempting to speculate that the depletion of these molecules
promotes spine loss.
Another factor that has been implicated in A-induced neu-
ronal dysfunction is PrPC. However, different groups have
obtained perplexingly disparate results in regard to this poten-
tial mediator. Indeed, PrPC has been shown to be required for
hAPP/A to impair neuronal functions in vitro (24, 25, 69–71)
and in vivo (27, 71). In contrast, other groups have identified
FIGURE 9.Overexpression of EphA2, another receptor tyrosine kinasewith a PDZ-bindingmotif, does not preventA-inducedGluN1depletion.A–D,
cultures of primary hippocampal neurons (DIV 2) fromwild-typemice were transduced with empty lentivirus (Empty) or lentivirus encoding EphA2 or EphB2.
At DIV 14, neurons were treated with A oligomers (2 M) or vehicle (Veh; 0.08% DMSO) for 2 h followed by Western blot analysis. A, representative Western
blots. B–D, quantification of sGluN1 (B), sEphA2 (C), and sEphB2 (D) signals. n 7–8 wells per condition from two independent experiments. In C, two-way
ANOVA revealeda significant (p	0.0001) effect ofAbutnotof lentivirus andno significant interactionbetween them. *,p	0.05; ***,p	0.001 versus vehicle
by Bonferroni test. Bars and error bars represent means and S.E., respectively.
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various hAPP/A-induced neuronal impairments that do not
depend on the presence of PrPC (28–30, 71, 72). In the current
study, PrPC ablation did not prevent A-induced sGluN1
depletion, contrary to results obtained by Um et al. (25).
Although differences between the specific A assemblies used
in these studies may explain the discrepancy (56), our findings
clearly demonstrate that some A oligomers can deplete sur-
face NMDARs independently of any mediation by PrPC. Con-
ceivably, different types of A oligomers cause neuronal dys-
functions by engaging different mediators. Further adding to
this complexity, our findings suggest that even the same type of
A oligomers can impair neuronal functions through distinct
pathways that, at a minimum, involve GluA2/GluN1 and
EphB2.
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